KEGG   DISEASE: HIV感染症
エントリ  
H01563                                                             

名称    
HIV感染症
概要    
The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). Two types of HIV has been characterized. HIV-1 is the most virulent and pathogenic strain. Worldwide, the predominant virus is HIV-1. The relatively uncommon HIV-2 type is concentrated in West Africa and is rarely found elsewhere. Infection with HIV occurs by transfer of blood, semen, and breast milk. The identification of HIV as the causative agent of AIDS catalyzed efforts to develop antiviral agents. The licenced anti-HIV drugs fall into some categories: reverse transcriptase inhibitors (NRTIs and NNRTIs), integrase inhibitors, protease inhibitors (PIs), fusion inhibitors (FIs), and coreceptor inhibitors. The advent of highly active antiretroviral therapy (HAART) as the standard of care for the treatment of HIV infection was seminal in reducing the morbidity and mortality associated with HIV infection and progression to AIDS. Combination antiretroviral therapy dramatically suppresses HIV replication and reduces the plasma HIV-1 viral load, resulting in significant reconstitution of the immune system.
カテゴリ  
感染症
階層分類  
感染症疾患 [BR:jp08401]
 ウイルス感染症
  ssRNA-RTウイルスによる感染症
   H01563  HIV感染症
ICD-11 による疾患分類 [BR:jp08403]
 01 Certain infectious or parasitic diseases
  Human immunodeficiency virus disease
   1C62  Human immunodeficiency virus disease without mention of tuberculosis or malaria
    H01563  HIV感染症
パスウェイ 
hsa05170  ヒト免疫不全ウイルス1感染
ネットワーク
nt06121  TLR signaling (viruses and bacteria)
nt06123  TNF signaling (viruses and bacteria)
nt06124  Chemokine signaling (viruses)
nt06129  MHC presentation (viruses)
nt06130  Cell cycle (viruses)
nt06131  Apoptosis (viruses and bacteria)
nt06134  CGAS-STING signaling (viruses and bacteria)
nt06150  Cytokine-cytokine receptor interaction (viruses)
nt06161  Human immunodeficiency virus type 1 (HIV-1)
  エレメント
N00431  HIV gp120 to CXCR4-GNAI-PI3K-BAD signaling pathway
N00432  HIV gp120 to CXCR4-GNAQ-PLCB/G-calcineurin
N00434  HIV gp120 to CXCR4-GNB/G-RAC signaling pathway
N00436  HIV Tat to TLR2/4-NFKB signaling pathway
N00437  HIV Vpu to TLR2/4-NFKB signaling pathway
N00439  HIV Nef to TLR2/4-MAPK signaling pathway
N00440  HIV Vpu/Vif/Vpr to cGAS-STING signaling pathway
N00441  HIV gp120 to TNF-NFKB signaling pathway
N00442  HIV Nef to TNF-NFKB signaling pathway
N00443  HIV Vpr/Nef/Tat to TNF-NFKB signaling pathway
N00445  HIV Tat/Nef to TNF-p38 signaling pathway
N00447  HIV Vpr/Tat to TNF-JNK signaling pathway
N00448  HIV Tat/Nef to crosstalk between extrinsic and intrinsic apoptotic pathways
N00449  HIV Tat/Nef to crosstalk between extrinsic and intrinsic apoptotic pathways
N00450  HIV Tat to intrinsic apoptotic pathway
N00451  HIV Tat to intrinsic apoptotic pathway
N00452  HIV Nef to intrinsic apoptotic pathway
N00453  HIV Vpr to intrinsic apoptotic pathway
N00454  HIV Vpr to intrinsic apoptotic pathway
N00456  HIV Vpr to CDC25-cell cycle G2M
N00457  HIV Vpr to cell cycle G2M
N00458  HIV Vpr to CDC25-cell cycle G2M
N00460  HIV Vpr to WEE1-cell cycle G2M
N00461  HIV Nef to antigen processing and presentation by MHC class I molecules
N01211  HIV gp120 to CCR5 signaling
N01254  HIV gp120 to CXCR4 signaling
病原体   
Human immunodeficiency virus 1 (HIV-1) [GN:T40001]
Human immunodeficiency virus 2 (HIV-2) [GN:T40002]
治療薬   
リトナビル [DR:D00427]
ネルフィナビルメシル酸塩 [DR:D00899]
ホスアンプレナビルカルシウム水和物 [DR:D02867]
アタザナビル硫酸塩 [DR:D01276]
ダルナビルエタノール付加物 [DR:D06478]
ジドブジン [DR:D00413]
ラミブジン [DR:D00353]
アバカビル硫酸塩 [DR:D00891]
テノホビルジソプロキシルフマル酸塩 [DR:D01982]
エムトリシタビン [DR:D01199]
ネビラピン [DR:D00435]
エファビレンツ [DR:D00896]
エトラビリン [DR:D04112]
リルピビリン塩酸塩 [DR:D09958]
ドラビリン [DR:D10624]
ラルテグラビルカリウム [DR:D07133]
ドルテグラビルナトリウム [DR:D10113]
ジドブジン・ラミブジン [DR:D07507]
アバカビル硫酸塩・ラミブジン [DR:D08775]
エムトリシタビン・テノホビルジソプロキシルフマル酸塩 [DR:D02297]
リルピビリン塩酸塩・テノホビルジソプロキシルフマル酸塩・エムトリシタビン [DR:D10571]
エルビテグラビル・コビシスタット・エムトリシタビン・テノホビルジソプロキシル [DR:D10756]
ロピナビル・リトナビル [DR:D02498]
ドルテグラビル・アバカビル・ラミブジン [DR:D10600]
ダルナビルエタノール付加物・コビシスタット [DR:D10832]
エムトリシタビン・テノホビルアラフェナミド [DR:D10835]
エルビテグラビル・コビシスタット・エムトリシタビン・テノホビルアラフェナミド [DR:D10755]
エムトリシタビン・リルピビリン・テノホビルアラフェナミド [DR:D10836]
ビクテグラビル・エムトリシタビン・テノホビルアラフェナミド [DR:D11039]
ドルテグラビルナトリウム・リルピビリン塩酸塩 [DR:D11282]
ダルナビル・コビシスタット・エムトリシタビン・テノホビルアラフェナミド [DR:D11382]
ドルテグラビル・ラミブジン [DR:D11522]
マラビロク [DR:D06670] (CCR5指向性)
エンフビルチド [DR:D02499]
エルビテグラビル [DR:D06677]
コメント  
See also H00406 Acquired immunodeficiency syndrome (AIDS).
リンク   
ICD-11: 1C62
ICD-10: B24
MeSH: D015658
文献    
  著者
Yousaf MZ, Zia S, Babar ME, Ashfaq UA
  タイトル
The epidemic of HIV/AIDS in developing countries; the current scenario in Pakistan.
  雑誌
Virol J 8:401 (2011)
DOI:10.1186/1743-422X-8-401
文献    
PMID:18928385 (drug)
  著者
Hazuda D, Iwamoto M, Wenning L
  タイトル
Emerging pharmacology: inhibitors of human immunodeficiency virus integration.
  雑誌
Annu Rev Pharmacol Toxicol 49:377-94 (2009)
DOI:10.1146/annurev.pharmtox.011008.145553
文献    
PMID:15934866 (drug)
  著者
De Clercq E
  タイトル
Emerging anti-HIV drugs.
  雑誌
Expert Opin Emerg Drugs 10:241-73 (2005)
DOI:10.1517/14728214.10.2.241
LinkDB    

» English version

DBGET integrated database retrieval system